<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808039</url>
  </required_header>
  <id_info>
    <org_study_id>RMC 2016-3</org_study_id>
    <nct_id>NCT02808039</nct_id>
  </id_info>
  <brief_title>Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial</brief_title>
  <official_title>Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <brief_summary>
    <textblock>
      to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a
      hyperreactive phase of platelet function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the study will be composed of a cohort of patients , who completed 12 months of DAPT with
      Ticagrelor (standard recommended dose for ACS - 90 mg BID), did not experience any clinical
      or adverse event during this time period and are about to discontinue Ticagrelor. We intend
      to measure the platelet reactivity for each patient on 4 time points - prior to cessation of
      Ticagrelor (i.e. while still on DAPT) and 1,4 and 12 weeks post discontinuation of therapy.
      There will not be a control group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity</measure>
    <time_frame>from 1 week prior to 12 weeks post DAPT cessation</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dual Antiplatelet Therapy</condition>
  <condition>Platelet Reactivity</condition>
  <arm_group>
    <arm_group_label>DAPT patients</arm_group_label>
    <description>Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet reactivity testing</intervention_name>
    <description>assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)</description>
    <arm_group_label>DAPT patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent coronary stent implantation and completed 12 months of DAPT regimen
        with Ticagrelor with no clinical or adverse events.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18

          -  underwent coronary stent implantation due to ACS

          -  completed 12 month of DAPT regimen containing Ticagrelor at standard dose (90 mg BID)

        Exclusion Criteria:

          -  any ischemic or bleeding events while under Ticagrelor

          -  any other Ticagrelor associated adverse effects

          -  planned for continuation of Ticagrelor for more than 12months post stenting according
             to the judgment of the attending physician.

          -  Unable to make informed consent .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Witberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eli Lev, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin Medical Center, Department of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Witberg, MD</last_name>
    <phone>(+972)528478828</phone>
    <email>vitberguy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eli Lev, MD</last_name>
    <phone>(+972)504065490</phone>
    <email>elev@tmhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center - Hsharon Campus</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Witberg, MD</last_name>
      <phone>9+972)528478828</phone>
      <email>vitberguy@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Eli Lev, MD</last_name>
      <phone>9+972)504065490</phone>
      <email>elev@tmhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Guy Witberg</investigator_full_name>
    <investigator_title>Dr Guy Witberg, MD department of cardiology , Rabin medical centre</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

